Me Therapeutics Holdings (CSE: METX; FSE: Q9T) has announced that the United States Patent Office (USPTO) has granted its subsidiary, ME Therapeutics, a patent for its lead G-CSF antibody candidate.
According to ME, the company is advancing its broader drug development and discovery programs for cancer.
In a statement, Salim Dhanji, CEO of ME, commented, “We are pleased with the business and scientific progress we have made across our pipeline as we work towards bringing novel immune-oncology drugs to patients worldwide who have limited treatment options.”
He added, “This quarter we reached several key milestones for our lead G-CSF antibody candidate that keep us on our pathway to the clinic, including securing a U.S. patent and moving forward cell line development in preparation for Good Manufacturing Practices (GMP). We also continued to progress our therapeutic mRNA and in vivo CAR programs through preclinical testing and discovery research.”
